and here's a little more about the actual drug (which I suppose will be part of "pre-clinical" on the list)
Neutrazumab - a C5a Receptor antagonist
G2’s lead programme is the development of an anti-C5aR receptor antibody for the treatment of Rheumatoid Arthritis. This well validated receptor binds the complement component C5a, one of the most potent inflammatory mediators in the body. C5aR is essential for a wide range of inflammatory reactions, such as in Rheumatoid Arthritis, Asthma, COPD, sepsis and reperfusion injuries. C5aR is perhaps one of the most promising targets for inflammatory diseases, but there are few effective drugs targeting this receptor. However, monoclonal antibodies represent a highly promising approach because of their safety and pharmacokinetic characteristics.
G2 has developed several murine antibodies which completely block C5a activity and prevent chemotaxis. They have also been validated in vivo and show near-complete reversal of inflammation in animal models. These antibodies therefore represent an ideal anti-inflammatory drug candidate with wide applicability coupled with the low toxicity typical of antibody therapies.
G2 is the only company to have developed antibodies to C5aR with such a strong anti-inflammatory effect. The company intends to take the best performing candidates into pre-clinical development.
G2 expects to develop anti-C5aR therapies for a number of additional indications, including transplantation and other reperfusion injuries (particularly cardiovascular indications such as Acute Myocardial Infarction and Coronary Artery Bypass Graft), Inflammatory Bowel Disease and Sepsis, and is considering a collaborative approach to some or all of these indications.